Genmab A/S GMAB
At closeNov 6, 2026, 6:07 PM EST
After hours · Nov 6, 6:07 PM ET
- YTD
- +74.12%
- 1 year
- +85.96%
- Market cap
- 32.98B
- Revenue (ttm)
- 4.13B
- Profit margin
- 19.07%
- EPS (ttm)
- 1.17
- Shares out
- 614.90M
- P/E ratio
- 45.84
- Forward P/E
- 33.94
- YTD return
- +74.12%
- 1-year return
- +85.96%
- Volume
- 7.83M
- Avg volume
- 4.05M
- Open
- 52.36
- Previous close
- 52.74
- Day's range
- 51.22 – 54.15
- 52-week range
- 23.85 – 57.29
- Beta
- 0.55
- Analysts
- Strong Buy
- Price target
- 64.96 (+21.1%)
- Earnings date
- Feb 16, 2027
5D -2.85 (-5.05%)
Key statistics
- Enterprise value
- 36.67B
- PEG ratio
- 7.85
- Price / sales
- 7.98
- Price / book
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 24.90%
- Free cash flow
- 870.63M
- Total cash
- 1.51B
- Total debt
- 5.27B
- Return on equity
- 14.00%
- Short % of float
- 1.09%
- 50-day average
- 38.79
- 200-day average
- 30.94
Analyst view
Consensus: strong buy
- Target (low)
- 48.00
- Target (mean)
- 64.96
- Target (high)
- 80.00
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 0.30 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.36 | 0.56 | +0.20 | +55.56% |
| Aug 6, 2026 | Jun 30, 2026 | 0.37 | 0.54 | +0.17 | +45.95% |
| May 7, 2026 | Mar 31, 2026 | 0.15 | 0.087 | -0.06 | -42.00% |
| Feb 17, 2026 | Dec 31, 2025 | 0.46 | 0.05 | -0.41 | -89.13% |
| Nov 6, 2025 | Sep 30, 2025 | 0.48 | 0.65 | +0.17 | +35.42% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 29, 2026 | Truist Securities | reit | Buy | Buy |
| Oct 29, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 26, 2026 | TD Cowen | main | Buy | Buy |
| Oct 26, 2026 | JP Morgan | up | Neutral | Overweight |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- genmab.com
News
Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate 
Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est 
Genmab Q3 2026 Earnings Call Transcript 
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting 
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled 
Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57 
Guggenheim Maintains Buy on Genmab, Raises Price Target to $80 
Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67 
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70 
Genmab Stock Hits 52-Week High - Here's Why
Your note
Sign in to keep a note on GMAB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2.10% | 13,133,131 | 704.33M | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 1.82% | 11,368,161 | 609.67M | Jun 29, 2026 |
| Alliancebernstein L.P. | 1.39% | 8,644,877 | 463.62M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 1.10% | 6,865,000 | 368.17M | Jun 29, 2026 |
| Deep Track Capital, Lp | 0.91% | 5,650,000 | 303.01M | Jun 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 0.80% | 4,975,324 | 266.83M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Biotechnology ETF | 0.69% | 4,322,251 | 231.80M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 0.50% | 3,121,944 | 167.43M | Sep 29, 2026 |
| NEW PERSPECTIVE FUND | 0.49% | 3,078,594 | 165.10M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 0.08% | 520,700 | 27.93M | Jul 30, 2026 |
| American Century ETF Trust-Avantis International Equity ETF | 0.08% | 500,718 | 26.85M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.06% | 350,000 | 18.77M | Jul 30, 2026 |